Reports about its effectiveness are conflicting. Continuing clinical assessment and muscle enzyme abnormalities guide the duration of treatment. Significant morbidity is associated with these diseases, as is significant morbidity as a result of the drugs used in treatment. Some deaths are due to malignancy, which is associated with dermatomyositis. Survival is less likely for women and African Americans.
Most patients improve with therapy.
The immunopathologic and inflammatory differences between dermatomyositis, polymyositis and sporadic inclusion body myositis. Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. However, as medical science is constantly changing and human error is always possible , the authors, editors, and publisher or any other party involved with the publication of this text do not warrant the information in this text is accurate or complete, nor are they responsible for omissions or errors in the text or for the results of using this information. The reader should confirm the information in this text from other sources prior to use.